HGH Somatropin

What HGH Somatropin is

Growth hormone (GH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotrophs of the anterior pituitary gland ^[1]. The endogenous protein is a 22 kDa single-chain polypeptide consisting of 191 amino acids stabilized by two disulfide bonds ^[2]. Its biological roles extend well beyond linear growth: it fosters healthy body composition by increasing muscle and reducing fat mass, maintains normal blood glucose levels, and promotes a favorable lipid profile ^[1]. The regulatory counterpart, somatostatin, suppresses GH release from the pituitary, and the liver-derived mediator IGF-1 accounts for most circulating anabolic effects downstream of GH secretion ^[3].

The modern era of somatropin research began in 1979, when Goeddel and colleagues expressed the gene for human GH in Escherichia coli, enabling bacterial production of the protein in large quantities ^[1]. In 1985, Genentech became the first company to market recombinant human GH (rhGH), commercially designated somatropin ^[1]. The recombinant molecule is bioidentical in amino-acid sequence to pituitary-derived GH, eliminating the infectious risks associated with cadaveric pituitary extracts that had previously been the only source of therapeutic GH. Multiple brand-name products—including Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, and Saizen—subsequently received regulatory approval from agencies such as the U.S. FDA, each carrying indication-specific labeling [4, 5].

What it is being researched for

1. Pediatric Growth Hormone Deficiency

The most extensively documented application of somatropin is in children with confirmed growth hormone deficiency (GHD). A landmark German multicentre clinical trial enrolled 77 GHD patients with heights at least 2.5 standard deviations below the normal mean and demonstrated substantial increases in height velocity with recombinant somatropin, and no anti-GH antibodies were detected in any patient ^[6]. A French multicentre open trial in 50 GHD children similarly reported mean growth rates rising from approximately 3.8 cm/year to 9.9 cm/year, with adverse events described as uncommon and probably unrelated to treatment ^[7]. More recently, a Phase 3 randomised controlled trial comparing once-weekly somatrogon with once-daily somatropin in 228 prepubertal GHD children confirmed that daily somatropin achieved height velocities around 9.78 cm/year over 12 months, establishing it as an active comparator benchmark for novel long-acting formulations ^[8]. These and comparable studies underpin the FDA-approved indication for somatropin in pediatric GHD [4, 5].

2. Adult Growth Hormone Deficiency and Body Composition

Adult-onset or childhood-onset GHD is associated with decreased lean body mass, increased visceral fat, reduced bone mineral density, and impaired quality of life. Research across multiple randomised controlled trials in GH-deficient adults has consistently documented increases in lean body mass and decreases in fat mass, particularly visceral adipose tissue, with effects correlated with achieved IGF-1 levels ^[2]. A study in adults with panhypopituitarism reported measurable improvements in lean body mass and bone mineral density after sustained somatropin research exposure, with all six patients reporting improved well-being ^[9]. The FDA-approved Norditropin prescribing label specifically indicates somatropin for adults with GHD arising from pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma ^[5], and the Omnitrope label extends this to both adult-onset and childhood-onset GHD ^[4].

3. Bone Mineral Density and Skeletal Health

GH deficiency is associated with decreased bone mineral density (BMD) and increased fracture risk ^[10]. A meta-analysis of randomised and prospective studies found that recombinant human GH therapy led to a significant increase in lumbar spine and femoral neck BMD in controlled studies lasting more than one year, with effects influenced by gender, age, and treatment duration—with larger increases observed in men than women ^[10]. A separate systematic review and meta-analysis evaluating rhGH in persons aged 50 and older with normal pituitary function found only small, nonsignificant increases in BMD when compared with placebo, though GH had a significant effect on several bone metabolism biomarkers, indicating biological activity even where BMD endpoints were not met ^[11]. These findings highlight that the bone effects of somatropin appear most robust in the context of confirmed GHD and may be more limited in individuals with intact pituitary function.

4. HIV-Associated Wasting and Cachexia

HIV-associated wasting is characterised by progressive loss of lean body mass and bodyweight, and remains a clinical concern even in the era of highly active antiretroviral therapy ^[12]. Somatropin (recombinant mammalian cell-derived GH, marketed as Serostim) received FDA approval as the only growth hormone indicated to increase lean body mass, bodyweight, and physical endurance in this condition ^[12]. A large randomised double-blind trial demonstrated statistically significant increases in lean body mass, bodyweight, and work output on a treadmill exercise measure of physical function, alongside a significant decrease in body fat compared with placebo ^[13]. Mechanistically, somatropin produces protein anabolic and anticatabolic effects in HIV-associated wasting, including increased nitrogen retention and decreased protein oxidation ^[13]. Available clinical data indicate that somatropin does not increase HIV replication in patients concurrently receiving antiretroviral medication ^[13].

5. Turner Syndrome and Genetic Short Stature Conditions

Turner syndrome (TS), a chromosomal condition affecting approximately 1 in 2,500 females, is associated with short stature and impaired growth. Somatropin is FDA-approved for short stature associated with Turner syndrome [4, 5], and clinical guidelines support its use in this population ^[5]. The FDA has similarly approved somatropin for other genetic short-stature conditions including Noonan syndrome, short stature homeobox-containing gene (SHOX) deficiency, Prader-Willi syndrome, and children born small for gestational age (SGA) who do not achieve catch-up growth ^[4]. In Prader-Willi syndrome specifically, a randomised active-controlled Phase III trial in infants and toddlers under two years of age found that 52 weeks of rhGH treatment produced significant increases in height standard deviation score and lean body mass, and significant decreases in percent body fat in both treatment groups, with similar incidences of adverse events ^[14].

6. Metabolic Regulation and Lipid Homeostasis

Beyond its anabolic effects, somatropin exerts direct metabolic actions that are studied independently of IGF-1 signalling. GH acts on adipocytes to stimulate lipolysis—mobilising free fatty acids from stored triglycerides—while suppressing lipoprotein lipase activity, resulting in net reductions in fat mass particularly in the visceral compartment ^[2]. GH also modulates carbohydrate metabolism; at the cellular level it has been observed to reduce insulin sensitivity and influence blood glucose homeostasis, which is why glucose tolerance is monitored as a safety endpoint in clinical research involving somatropin [4, 5]. These dual metabolic roles—promoting fat mobilisation while maintaining lean mass—make somatropin a reference molecule in research into the endocrine regulation of energy balance and substrate partitioning ^[1].

7. Neuromuscular and Catabolic Conditions

Preclinical studies have shown that growth hormone and its primary mediator IGF-1 have potential to increase muscle mass and strength, motivating exploratory clinical research in neuromuscular diseases ^[15]. A multicentre, randomised, double-blind, placebo-controlled crossover pilot trial evaluated the efficacy and safety of somatropin in 19 patients with spinal muscular atrophy (type II/III); the study found that somatropin treatment did not significantly improve upper limb muscle strength or functional motor outcomes in this specific population, highlighting the importance of indication-specific evidence and the limits of extrapolating body-composition benefits to primary neuromuscular disease ^[15]. Research has also been conducted in severely burned patients, where a ClinicalTrials.gov-registered study (NCT03038594) evaluated rhGH for muscle regeneration, measuring lean body mass, muscle strength, exercise endurance, and hypertrophic scar development over a two-year follow-up window ^[16].

How it is thought to work

Somatropin exerts its biological effects through both direct receptor-mediated signalling and the indirect induction of insulin-like growth factor-1 (IGF-1) ^[2]. Upon binding to the growth hormone receptor (GHR)—a class I cytokine receptor expressed prominently in the liver, cartilage, muscle, and adipose tissue—somatropin triggers dimerisation of the receptor and activation of the associated intracellular tyrosine kinase Janus kinase 2 (JAK2) [2, 17]. Activated JAK2 phosphorylates tyrosine residues on the GHR itself, creating docking sites for signal transducer and activator of transcription (STAT) proteins, particularly STAT5b ^[2]. STAT5b dimerises and translocates to the nucleus, where it drives transcription of target genes—most importantly the gene encoding IGF-1, produced predominantly in the liver [2, 17]. GHR signalling also activates parallel pathways: the MAPK/ERK pathway promotes chondrocyte proliferation and differentiation at the growth plate directly, while the PI3K/Akt pathway mediates glucose and protein metabolism and cell survival [2, 17].

The resulting IGF-1 then acts in endocrine, paracrine, and autocrine modes on target tissues ^[3]. In bone, IGF-1 stimulates osteoblast and chondrocyte activity to promote skeletal growth and mineralisation ^[17]. In the liver, activated GHR signalling also increases production of IGF binding protein-3 (IGFBP-3) and acid-labile subunit (ALS), which bind IGF-1 in a ternary complex to extend its circulating half-life ^[2]. Separately from the IGF-1 axis, GH acts directly on adipocytes to stimulate hormone-sensitive lipase, promoting lipolysis and reducing stored triglycerides ^[2]. Together, these mechanisms explain how somatropin can simultaneously promote anabolism via the JAK2/STAT5/IGF-1 axis, stimulate chondrocyte proliferation via MAPK, and alter metabolic substrate utilisation via PI3K/Akt, producing its characteristic profile of effects across bone, muscle, and adipose tissue ^[17].

Where the evidence stands

The human clinical evidence base for somatropin is among the largest for any recombinant peptide, spanning decades of randomised controlled trials (RCTs), meta-analyses, and long-term observational studies, most conducted in populations with confirmed GHD. Multiple Phase 3 RCTs in paediatric GHD have consistently shown somatropin to produce significant increases in annualised height velocity, normalise IGF-1 levels, and be well tolerated with low immunogenicity [6, 7, 8]. In adults with GHD, meta-analyses of RCTs demonstrate significant improvements in lumbar spine and femoral neck BMD after more than 12 months of therapy, with consistent gains in lean body mass and reductions in visceral fat ^[10]. In HIV-associated wasting, a large double-blind placebo-controlled trial established significant benefits in lean body mass and physical function, supporting the FDA approval of Serostim for this indication [12, 13]. In Turner syndrome, Prader-Willi syndrome, and related genetic conditions, multiple RCTs and Phase 3 studies underpin current regulatory approvals [4, 5, 14].

Despite this substantial evidence, important limitations and evidence gaps persist. Most long-term human data come from populations with pathological GHD; effects in individuals with normal pituitary function are less well characterised. A systematic review and meta-analysis of rhGH for osteoporosis in older adults with normal pituitary function found only small, nonsignificant BMD changes, suggesting that results from GHD populations do not automatically generalise ^[11]. A pilot RCT in spinal muscular atrophy found no significant improvement in primary neuromuscular endpoints despite preclinical promise, illustrating that mechanistic rationale does not always translate into clinical benefit in heterogeneous disease contexts ^[15]. Safety considerations flagged in FDA prescribing information include impaired glucose tolerance, potential for neoplasm progression in at-risk patients, and respiratory risks in Prader-Willi syndrome, underscoring the need for ongoing monitoring in all research and clinical settings [4, 5]. Long-term fracture risk data remain limited even in GHD adults, and larger, longer studies continue to be called for ^[10].

Frequently asked questions

What is HGH Somatropin and how is it different from naturally produced growth hormone?

Somatropin is a recombinant form of human growth hormone (rhGH) that is bioidentical in amino-acid sequence to the 191-amino-acid GH produced by the anterior pituitary gland. It is manufactured using recombinant DNA technology—originally in bacterial expression systems and later in mammalian cell lines—rather than extracted from human tissue. This production method eliminates the infectious disease risks associated with cadaveric pituitary-derived GH and allows consistent, scalable manufacturing.

What conditions is somatropin approved to treat?

The U.S. FDA has approved somatropin for several indications, including growth failure due to GH deficiency in children and adults, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, short stature homeobox-containing gene (SHOX) deficiency, chronic renal insufficiency, idiopathic short stature, children born small for gestational age, and HIV-associated wasting in adults. Specific brand products carry specific subsets of these indications in their prescribing labelling. All approved uses require a clinical diagnosis and physician supervision.

How does somatropin work in the body at a molecular level?

Somatropin binds to the growth hormone receptor (GHR), a dimeric class I cytokine receptor on cell surfaces in the liver, muscle, bone, and adipose tissue. This triggers activation of the intracellular kinase JAK2, which phosphorylates STAT proteins—especially STAT5b—that then translocate to the nucleus and switch on growth-related genes, most importantly the gene for IGF-1. Parallel signalling through the MAPK/ERK and PI3K/Akt pathways mediates additional effects on cell proliferation and metabolism. IGF-1 produced mainly by the liver then circulates to amplify these effects throughout the body.

What is the role of IGF-1 in somatropin research?

IGF-1 (insulin-like growth factor-1) is the primary downstream mediator of somatropin's anabolic actions. When somatropin binds to its receptor in the liver, it stimulates IGF-1 gene transcription and IGF-1 secretion. IGF-1 then acts in an endocrine (systemic), paracrine (local tissue), and autocrine (cell-autonomous) manner to stimulate bone growth, muscle protein synthesis, and tissue repair. Circulating IGF-1 levels are commonly measured in research studies as a pharmacodynamic marker of somatropin activity.

What does the human clinical evidence show about somatropin and bone mineral density?

A meta-analysis of RCTs in adults with GH deficiency found significant increases in lumbar spine and femoral neck BMD after more than 12 months of rhGH therapy, though effects were influenced by age, sex, and treatment duration. By contrast, a separate meta-analysis evaluating rhGH in older adults with normal pituitary function found only small, non-significant BMD changes. Current evidence most reliably supports skeletal benefits in the GH-deficient population; broader anti-osteoporosis applications in those with intact pituitary function remain an area of active investigation.

Is somatropin studied for HIV-associated wasting?

Yes. Serostim, a mammalian cell-derived formulation of somatropin, is the only rhGH product with FDA approval specifically for HIV-associated wasting. A large randomised double-blind placebo-controlled trial demonstrated significant increases in lean body mass, bodyweight, and treadmill-measured work output, with a significant reduction in body fat compared with placebo. Clinical data have not shown an increase in HIV replication when somatropin is used alongside antiretroviral therapy.

Are there research areas where somatropin has not shown the expected benefit?

Yes. A multicentre randomised double-blind placebo-controlled crossover pilot trial in patients with spinal muscular atrophy (type II/III) found that somatropin did not significantly improve upper limb muscle strength or functional motor outcomes, despite preclinical evidence that GH and IGF-1 can increase muscle mass and strength. This illustrates that mechanistic rationale derived from GHD or body-composition research does not automatically predict benefit in primary neuromuscular diseases.

What safety signals does regulatory labelling flag for somatropin?

FDA prescribing information for approved somatropin products lists several monitored risks, including impaired glucose tolerance and unmasking of diabetes mellitus, neoplasm progression or recurrence in patients with pre-existing tumours, and risk of upper airway obstruction and sleep apnea in patients with Prader-Willi syndrome. Increased risk of a second neoplasm has been noted in childhood cancer survivors treated with somatropin, particularly meningiomas in those who received cranial radiation. Research programs in these populations require ongoing safety monitoring.

How was recombinant somatropin first developed?

In 1979, Goeddel and colleagues succeeded in expressing the gene for human GH in Escherichia coli bacteria, enabling large-scale production for the first time. In 1985, Genentech received the first approval to market this recombinant GH (somatropin), marking the transition away from cadaveric pituitary extracts—which had been withdrawn due to links to fatal Creutzfeldt-Jakob disease. Subsequent manufacturing advances included mammalian cell expression systems that produce GH with glycosylation patterns more closely matching the pituitary form.

What is the difference between somatropin and growth hormone secretagogues or GH-releasing peptides?

Somatropin is the recombinant human GH protein itself—it acts directly on GH receptors without relying on the pituitary. Growth hormone secretagogues (GHS) and GH-releasing peptides (GHRPs) are smaller molecules that stimulate the pituitary to release endogenous GH, rather than providing exogenous GH directly. Because somatropin bypasses pituitary regulation entirely, its effects are not limited by the individual's native GH secretory capacity, which is relevant in populations with pituitary damage or deficiency.

Glossary

Somatropin

The International Nonproprietary Name (INN) for recombinant human growth hormone (rhGH) that is bioidentical in sequence to the 191-amino-acid GH secreted by the anterior pituitary gland.

IGF-1 (Insulin-like Growth Factor-1)

A liver-produced peptide hormone, upregulated by GH receptor signalling, that mediates most of somatropin's anabolic effects on bone, muscle, and other tissues.

Growth Hormone Receptor (GHR)

A class I cytokine receptor expressed on target cells in the liver, cartilage, muscle, and adipose tissue that binds somatropin and initiates intracellular signalling cascades including JAK2/STAT5.

JAK2/STAT5 Pathway

The primary intracellular signalling axis activated upon GH-GHR binding, in which Janus kinase 2 phosphorylates STAT5b transcription factors that translocate to the nucleus to drive IGF-1 and other target gene expression.

Growth Hormone Deficiency (GHD)

A clinical condition in which the pituitary gland produces insufficient endogenous growth hormone, leading to impaired growth in children and adverse changes in body composition, bone density, and metabolic parameters in adults.

IGFBP-3 (IGF Binding Protein-3)

A circulating protein whose hepatic production is upregulated by GH signalling; it binds IGF-1 in a ternary complex that extends IGF-1's half-life in the bloodstream.

Recombinant DNA Technology

The molecular biology technique used to introduce the human GH gene into a host organism (such as E. coli or mammalian cells) to produce large, consistent quantities of the recombinant protein somatropin.

Height Velocity (HV)

A clinical measure of the rate of linear growth in children, expressed in centimetres per year, and commonly used as the primary efficacy endpoint in paediatric GHD clinical trials of somatropin.

References

1. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review — PMC / Patient Preference and Adherence
2. The growth hormone receptor: mechanism of activation and clinical implications — Nature Reviews Endocrinology
3. Central and peripheral actions of somatostatin on the growth hormone–IGF-I axis — Journal of Clinical Investigation
4. Omnitrope (somatropin) Prescribing Information — FDA — U.S. Food and Drug Administration (FDA)
5. Norditropin (somatropin) injection — FDA Prescribing Information — U.S. Food and Drug Administration (FDA)
6. Multicentre clinical trial of authentic recombinant somatropin in growth hormone deficiency — PubMed / Acta Paediatrica Scandinavica Supplement
7. Preliminary results of authentic recombinant somatropin treatment in human growth hormone deficient children (French Collaborative Study) — PubMed / Acta Paediatrica Scandinavica Supplement
8. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study — PubMed / Journal of Clinical Endocrinology & Metabolism
9. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism — PubMed / Acta Endocrinologica (Copenhagen)
10. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis — PubMed / Journal of Clinical Endocrinology & Metabolism
11. Effects of Recombinant Human Growth Hormone for Osteoporosis: Systematic Review and Meta-Analysis — Canadian Journal on Aging / Cambridge University Press
12. Spotlight on mammalian cell-derived somatropin in HIV-associated wasting — PubMed / BioDrugs
13. Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection — PubMed / BioDrugs
14. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial — PMC / Orphanet Journal of Rare Diseases
15. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study — PubMed / European Journal of Paediatric Neurology

Other guides in Growth Hormone

• CJC-1295 (No DAC) + Ipamorelin — CJC-1295 (No DAC) is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH) that stimulates pulsatile growth hormone …
• HGH (Kit) — Human Growth Hormone (HGH), also known as somatropin, is a 191-amino acid polypeptide naturally produced by the anterior pituitary gland and…
• IGF-1 LR3 — IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a synthetic, 83-amino-acid analog of human IGF-1, engineered in the early 1990s to resis…
• Ipamorelin — Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin receptor (GHS-…
• Sermorelin — Sermorelin (GHRH 1–29) is a synthetic 29-amino-acid peptide analog of endogenous growth hormone-releasing hormone (GHRH) that binds receptor…